Trial Profile
A retrospective analysis assessing clinical efficacy and safety of anlotinib in previously-treated TET patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Thymic epithelial tumour
- Focus Therapeutic Use
- 19 Oct 2022 New trial record
- 13 Sep 2022 Results of retrospective analysis assessing efficacy and safety of anlotinib in previously-treated TET patients presented at the 47th European Society for Medical Oncology Congress